Low expression of ZHX1 and ZHX2 impacts on the prognosis of chronic lymphocytic leukemia

Experimental evidence points to the role of Zinc fingers and homeoboxes protein 1 and 2 (ZHX1 and ZHX2) in the development and progression of several types of cancer, including hematological malignancies. Here, we determined whether the altered expression of ZHX1 and ZHX2 has clinical implications in patients with CLL. Interestingly, CLL patients with low expression ZHX1 and ZHX2 presented higher WBC counts. Importantly, our data showed that CLL patients with cytogenetic alterations presented reduced transcriptional levels of ZHX1 and ZHX2 in comparison with patients with normal karyotype. Moreover, when stratifying CLL patients according to the karyotype prognosis value, we observed that the expression of ZHX1 and ZHX2 was significantly reduced in CLL patients presenting adverse karyotypes. Finally, we stratified patients according to the number of chromosomal aberrations and observed a negative association between ZHX1 and ZHX2 expression and the accumulation of chromosomal abnormalities in CLL patients. Our data showed that the low expression of ZHX1 and ZHX2 is associated with a worse prognosis in CLL, followed by a greater number of leukemic cells and unfavorable cytogenetics findings in the diagnosis. Further studies will be important to confirm the prognostic value of ZHX1 and ZHX2 in independent CLL cohorts. Supplementary Information The online version contains supplementary material available at 10.1186/s40364-021-00263-2.

To the Editor, Zinc fingers and homeoboxes protein 1 and 2 (ZHX1 and ZHX2) are two members of the zinc-finger and homeobox families, which act as transcriptional repressors. Experimental evidence points to the role of such ZHX members in the development and progression of several types of cancer, including hematological malignancies [1]. Nevertheless, the expression of ZHX members on CLL remains unknown.
In this article, we determined whether the altered expression of ZHX1 and ZHX2 has clinical implications in patients with CLL. Initially we accessed the BloodSpot database by the International Microarray Innovations in Leukemia (MILE) study group [2], which was performed in a cohort of 73 healthy bone marrow samples and 448 CLL patients. Additionally, ZHX1 and ZHX2 expression was determined by quantitative real-time PCR in peripheral blood mononuclear cells (PBMC) obtained from 51 CLL patients, diagnosed according to Matute's score, and treated at the University Hospital of the Medical School of Ribeirão Preto (University of São Paulo, Brazil). For comparison purposes, 8 samples of peripheral blood B-sorted cells from age-matched healthy volunteers were included. Flow cytometry analysis of ZAP70 expression was performed, following the identification of the CD19+ CD5+ population. Patients presenting at least 20% of leukemic cells expressing ZAP-70 were designated as "ZAP-70 positive". Cytogenetic analysis was performed by G-banding and according to the results, the prognostic classification of this cohort was determined as favorable, intermediate, and adverse [3,4]. The statistical analysis is described in the supplementary information file.
Data from the MILE study group showed that ZHX1 mRNA levels were increased in CLL (p ≤ .0001), regardless of the probe analyzed. Using the probe 203556_at, no differences regarding the expression of the ZHX2 gene between CLL and healthy bone marrow samples were found (p > 0.05). Conversely, the probe 1557706_at revealed an increased expression of this transcript in CLL samples (p = 0.002). In order to validate these data and explored possible prognostic implications in CLL, we decided to investigate the levels of expression of ZHX1 and ZHX2 in 51 patients with CLL and 8 B-cell samples obtained from healthy donors. The median age of patients was 65 years (range: 43-85), and 21 of them were female (41%). Overall, 35 patients were classified as Binet A, followed by 11 Binet B, and 5 Binet C. The expression of the ZHX1 (p > 0.05) and ZHX2 (p > 0.05) genes were similar between CLL and control samples (supplementary Fig. 1). Although we have not explored the functions of ZHX family members at a functional level, we speculate that such contrasting data between in silico analysis and our validation can be explained by the differences between control samples. While the bloodspot database uses bone marrow cells, the primary samples from our court were previously purified B-cell samples.
In order to compare the clinical and laboratorial features of CLL patients grouped according to ZHX1 and ≥ 3 aberrations: complex karyotype) and observed a negative association between ZHX1 and ZHX2 expression and the accumulation of chromosomal abnormalities in CLL patients (p = 0.002 and p = 0.003, respectively) (Fig. 1). Our data showed that the low expression of ZHX1 and ZHX2 is associated with a worse prognosis in CLL, followed by a greater number of leukemic cells and unfavorable cytogenetics findings in the diagnosis [5]. Recently, several studies have been conducted to unravel the influence of members of the ZHX family on cancer. Interestingly, ZHX1 was found to be down-regulated in renal cell carcinoma, and the mRNA reduction of this gene was associated with lower survival rates [6]. ZHX1 is also Fig. 1 ZHX1 and ZHX2 expression in CLL and association with WBC and cytogenetic findings. CLL patients with low expression of ZHX1 (a) and ZHX2 (b) showed higher WBC counts. Low expression of ZHX1 and ZHX2 was significantly associated with abnormal (c, d), adverse (e, f), and complex (g, h) karyotype. Mann-Whitney test was employed to compare differences between two groups. Kruskal-Wallis followed by the multiple comparison test (Dunn's) was used to compare differences between three groups downregulated in gastric cancer, and the reduced expression of this gene has been associated with other clinical parameters that are indicative of aggressive disease [7]. ZXH2 was found to have reduced expression in hepatocellular carcinoma, and the decreased levels of this gene were associated with the low survival of patients [8]. Moreover, the impact of ZHX2 on hematological neoplasms has been investigated. It was demonstrated that patients with multiple myeloma who have reduced ZHX2 expression tend to have a worse prognosis, with resistance to chemotherapy and unfavorable karyotype [9]. Besides, this gene acts as a tumor suppressor in Hodgkin lymphoma [10]. Considering our findings, we hypothesize that ZHX1 and ZHX2 may also play a role as tumor suppressor in CLL, the aberrant expression of these genes possibly contributing to an increase in the number of malignant cells and chromosomal instability.
To the best of our knowledge, our study represents the first step to demonstrate the prognostic impact of ZHX members in CLL. However, it is important to highlight that in our cohort, only 14% of the patients in the favorable prognosis group have del (13q), while in the adverse prognosis group, del (17p) and 11q23 is found in 29% of cases. We cannot rule out that some classic chromosomal changes may have been underestimated in this study. The fact that the samples were not analyzed using FISH method to identify these chromosomal alterations represents a limitation of this work. Further studies will be important to characterize the functional role of ZHX1 and ZHX2 in this leukemia and also to confirm the prognostic value of both genes in independent CLL cohorts.
Additional file 1: Fig. S1. Gene expression of ZHX1 and ZHX2 in CLL. ZHX1 gene expression was analyzed in CLL patients by accessing the probes 223213_s_at (A) and 223214_s_at (B) available in the Blood Spot database. (C) ZHX1 gene expression also was determined in CLL samples by real-time quantitative PCR. ZHX2 gene expression was analyzed in CLL patients, by accessing the probes 203556_at (D) and 1557706_at (E) available in the Blood Spot database. (F) ZHX2 gene expression also was determined in CLL samples by real-time quantitative PCR. Horizontal bars represent the median expression of the genes. Mann-Whitney test was employed to compare differences between the groups.